A Diamond in the Rough – Trends and Strategies in the Healthcare VC Market
Conference: Breakout Sessions
Track: Finance
Date: Tuesday May 4, 2010
Time: 4:00 PM - 5:30 PM
Location: McCormick Place, Chicago
Room: S405B
Description: While venture capital investment fell 51 percent in the 2009 second quarter—bringing funding for start-ups to the lowest level in 15 years—the biotechnology sector remains resilient, with a 54 percent increase in deals from the first quarter. This panel will explore the impact of the recession and drought in IPOs on VC funding, and the reasons why VC funding in the biotech industry is less susceptible to the pitfalls of a financial slowdown. VC panelists will discuss the newest trends in investment funding, their investment criteria and how it’s shaped during economic cycles, and the increasing hands-on approach of VC firms. They will also provide insight into what they look for when they invest in a start-up company. Biotech panelists will discuss the secret of their success in raising cash in a buyers’ market.
Objectives:
1. Explore the opportunities for life science entrepreneurs in this changing market.
2. Discuss how VC investment strategies have already changed and might evolve considering the proposed health care legislation.
3. Give predictions for VC investment in the future.
Eva Jack, MS - Chair
Managing Director, MedImmune Ventures, Inc
MedImmune
Steven Elms, MBA
Managing Partner, Aisling Capital
Aisling Capital LLC
Allan Marchington, PhD
Partner, Apposite Capital
Apposite Capital
Carole Nuechterlein
Head of Roche Venture Fund
F. Hoffmann - La Roche Ltd
Joseph Regan
VP Investments: Life Sciences
GrowthWorks Capital
Added by MedImmune on January 28, 2010